Your browser doesn't support javascript.
loading
Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation.
Luo, Xuemei; Chaves, Jose; Dhamane, Amol D; Dai, Feng; Latremouille-Viau, Dominick; Wang, Aolin.
Afiliación
  • Luo X; Pfizer, Inc., Health Economics and Outcomes Research, Groton, CT, USA.
  • Chaves J; Pfizer SLU, Internal Medicine, Global Medical Affairs, Madrid, Spain.
  • Dhamane AD; Bristol Myers Squibb, Lawrenceville, NJ, USA.
  • Dai F; Pfizer, Inc., Global Product Development, Groton, CT, USA.
  • Latremouille-Viau D; Analysis Group, Inc., Montréal, Quebec, Canada.
  • Wang A; Analysis Group, Inc., NY, New York, USA.
Am Heart J Plus ; 39: 100369, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38510996
ABSTRACT
Study

objective:

This study aimed to identify factors associated with delayed oral anticoagulant (OAC) treatment initiation among atrial fibrillation (AF) patients in United States (US) clinical practice.

Participants:

Medicare beneficiaries newly diagnosed with AF without moderate-to-severe mitral stenosis or a mechanical heart valve, were aged ≥65 years and prescribed OAC on or after 10/1/2015 through 2019 were included. Delayed and early OAC initiation were defined as >3 months and 0-3 months initiation from first AF diagnosis, respectively. Main outcome

measures:

Association between delayed OAC initiation and patient demographics, clinical and index OAC coverage and formulary characteristics was examined using multivariable logistic regression.

Results:

A total of 446,441 patients met the inclusion criteria; 30.0 % (N = 131,969) were identified as delayed and 70.0 % (N = 314,472) as early OAC initiation. Median age for both cohorts was 78 years. In the early and delayed OAC cohorts, 47.1 % and 47.6 % were male and 88.8 % and 86.6 %, were White, respectively. Factors associated with delayed OAC initiation (odds ratio; 95 % confidence interval) included Black race (1.29; 1.25 to 1.33), west region (1.29; 1.26 to 1.32), comorbidities such as dementia (1.27; 1.23 to 1.30), recent bleeding hospitalization (1.22; 1.18 to 1.27), prior authorization (1.69; 1.66 to 1.71), tier 4 formulary for index OAC at AF diagnosis (1.26; 1.22 to 1.30).

Conclusion:

Our study revealed that nearly one-third of Medicare patients with AF experienced delayed OAC initiation. Key patient characteristics found to be associated with delayed OAC initiation included race and ethnicity, comorbidities, and formulary restrictions.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Am Heart J Plus Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Am Heart J Plus Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos